Kenneth Agyei-Kyeremateng
A bit about me I am passionate about providing creative and pragmatic strategies that deliver innovative treatments to people that […]
Beyond the Cancer Vaccine: When the Asset Is No Longer a Sufficient Unit of Value
Moderna’s melanoma result highlights a widening gap between how oncology creates clinical value and how medicines are owned, evidenced and
Margaux Theys
I am passionate about turning complex science into insights that improve how patients are treated and cared for. Career highlights
ESMO Congress 2026
23rd – 27th October 2026Madrid, Spain Abstract The ESMO Congress is a highly influential global oncology meeting for clinicians, researchers,
Abstract: Why Two Brand for One Molecule? Strategic Implications of Dual-Brand Approaches for Orphan Designations, Revenue Thresholds and Pricing in Germany
Authors: Katharina Wolff-Kuhne, PhD; Malte Glüsen, MSc; Dr. Lydia Frick, MSc, PhD; Dr. Matthias P. Schönermark, PhD, MD. Kintiga, Hannover,
Abstract: Inclusion of Caregiver Quality-of-Life in Economic Evaluations: Global HTA Perspectives and Impact
Authors: Marieke Schurer, MSc; Melanie van Riemsdijk, PharmD, PhD. Kintiga, Ghent, Belgium. Abstract OBJECTIVES In health technology assessments (HTA), inclusion of
Abstract: Challenge of ATMP Reimbursement and Patient Access in a Changing UK Landscape
Authors: Ben Barron-Millar, PhD; Malcolm Boyd, MSc. Kintiga, Cambridge, United Kingdom. Abstract OBJECTIVES Advances therapy medicinal products (ATMPs) present significant challenges
Abstract: AI-Assisted Data Extraction for Systematic Literature Reviews in HTA: Accuracy and Efficiency within a NICE-Aligned Workflow
Authors: Praptee Ghimire, MSc; Ben Lanning, PhD; Tejas Pethkar, BSc; Anna Macbeth, BSc; Jessica Radford, BSc; Priscila Mazzola, PhD. Kintiga,
Delivering a Successful SMC Re‑Submission Through Strategic Alignment and Rapid Cross‑Functional Execution
The client faced a complex fourth re‑submission to the Scottish Medicines Consortium, with gaps in adverse event evidence, adherence‑related outcomes,
From JCA to AMNOG: What Survives Downstream?
When the first Joint Clinical Assessment for tovorafenib was published, I described it as an “empty grid”. Eight PICOs had
